In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting ...

Pneumonia is a lung infection that annually impacts millions of people around the globe, according to the Centers for Disease ...

SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...

French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience ...

According to the investigators of a newly published study on the waning of pneumococcal vaccines responses in people with inflammatory arthritis, pneumonia is a major cause of mortality in this ...

Pneumococcal pneumonia vaccine is under development for the treatment of pneumonia. It is a conjugate vaccine. It is administered through intramuscular as a liquid formulation. It is a new chemical ...

SK Bioscience and global pharmaceutical giant Sanofi signed an expanded agreement to jointly develop next-generation ...